The DOI matches its Crossref record.
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Abstract
OBJECTIVES: Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathogens. This randomized, double-blind, Phase III study evaluated the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) ≥ -10%] of clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 2 registration number NCT00509106 (http://clinicaltrials.gov/ct2/show/NCT00509106). RESULTS: The study enrolled 627 patients, 315 of whom received ceftaroline fosamil and 307 of whom received ceftriaxone. Patients in both treatment groups had comparable baseline characteristics. Clinical cure rates were as follows: CE population, 82.1% (193/235) for ceftaroline fosamil and 77.2% (166/215) for ceftriaxone [difference (95% CI), 4.9% (-2.5, 12.5)]; and MITTE population, 81.3% (235/289) for ceftaroline fosamil and 75.5% (206/273) for ceftriaxone [difference (95% CI), 5.9% (-1.0, 12.7)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE (mMITTE) population were 83.3% (35/42) and 70.0% (28/40) for ceftaroline fosamil and ceftriaxone, respectively. Ceftaroline fosamil and ceftriaxone were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations due to an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, hypokalaemia, insomnia and phlebitis, and the most common AEs for ceftriaxone-treated patients were diarrhoea, insomnia, phlebitis and hypertension. CONCLUSIONS: Ceftaroline fosamil achieved high clinical cure and microbiological response rates in patients hospitalized with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile that is similar to that of ceftriaxone and other cephalosporins. Ceftaroline fosamil is a promising agent for the treatment of CAP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Lin, J. C., Fierer, J., Aung, G., Johns, S., Thomas, A., Jahng, M., Fierer, J., & Fierer, J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0449-9 · Cited by 109
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-13 · Cited by 108
Metadata
- Authors
- Low, D. E., File, T. M., Eckburg, P. B., Talbot, G. H., David Friedland, H., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 2 investigators, Corral, J., Giugno, E., Gonzalez Arzac, M. D. R., Maurizi, D., Altclas, J., Ambasch, G., Jasovich, A., Minguez, A. R., Oliva, M. E., Teglia, O., Bergallo, C., Mastruzzo, M. A., Isabel Morera, G., Scapellato, P. G., Lamberghini, R., Mykietiuk, A., Remolif, C., Barros Monge, M. J., Enriqueta Campos Barker, M. I., Chernilo Steinmann, S. M., Gaete Gutierrez, P. A., Muñoz Vejar, S. S., Calvo Arellano, M. A., Chahin Anania, C. E., Jauregui Cruz, A., Amaya Tapia, G., Acuna Kaldman, M., Noriega, E., Matos Prado, E. D., Ramos, C., Andreeva, I., Abyshev, R., Antonovsky, Y. A., Balyuzek, M., Esina, A. L., Gorelov, A., Khrustalev, O. A., Kozlov, R. S., Novozhenok, V., Popova, V. B., Sobchenko, S., Trofimov, V., Yakovlev, S., Zhidkov, K., Ambert, L. G., Fierbinteau, C. G., Ionescu, V., Muresan, M. M., Tanaseanu, C. M., Georgiev, O., Hodzhev, V., Marinov, R., Metev, H., Peneva, M., Popov, D., Simeonova, M., Krastins, I., Lovcinovsk, V., Silins, V., Svarcberga, V., Bargon, J., Bauer, T., Bergmann, R., Meyer, F. J., Mueller, T., Welte, T., Glaeser, S., Hammerl, P., Kern, H., Krueger, S., Kujath, P., Lies, A., Schaberg, T., Schmalz, O., Schütte, W., Chazan, R., Górecka, D., Rogala, B., Antczak, A., Grodzicki, T., Jahnz—Rö, K., Milanowski, J., Nalepa, P., Wróbel-Rajzer, M., Szelerska-Twardosz, H., Grzelewska—Rzymowska, I., Kachel, T., Marciniak, A., Panaszek, B., Szczeklik, A., Kozielski, J., Harat, R., Jastrzebsk, D., Juszczak, J., Labij, V., Vetter, N., Bolitschek, J., Eckmayr, J., Molnár, S., Pápai-Székely, Z., Szegedi, J., Vinkler, I., Borscchivskyy, M., Dziublyk, O., Dzyak, G. V., Kraydaschenko, O., Mostovoy, Y. M., Rudyk, I. S., Sushko, V., Vizir, V., Bhattacharya, A. K., Chakrapan, M., D'Souza, G., Malpani, G. S., Mehta, P., Rao, K. N. M., & Talwar, D.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 66
- Issue
- suppl_3
- Pages
- iii33-iii44
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2916433178
- Cited by
- 185
- References
- 0
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. https://app.cochat.ai/papers/10.1093/jac/dkr097
- The paper
- Low, D. E., File, T. M., Eckburg, P. B., Talbot, G. H., David Friedland, H., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 2 investigators, Corral, J., Giugno, E., Gonzalez Arzac, M. D. R., Maurizi, D., Altclas, J., Ambasch, G., Jasovich, A., Minguez, A. R., Oliva, M. E., . . . Talwar, D. (2011). FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkr097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.